The Research & Development Committee
The Research & Development Committee consists of up to five
members elected by the Board
of Directors from among its members. One member is designated as
chair and one member is an employee representative.
The Board of Directors has in March 2019 elected the following
members to the Research & Development Committee:
Mackay (re-elected, member and chair since 2018;
Daniels (re-elected, member since the establishment in 2017;
Gregoire (re-elected, member since the establishment in 2017;
Rantzau (re-elected, member since 2018; employee representative;
Roles and responsibilities
The Research & Development Committee assists the Board with
oversight of a) the research and development strategy, b) the
pipeline, c) the R&D organisation, and d) other tasks on an ad hoc
basis as specifically decided by the Board.
The Research & Development Committee consists of three members
who are independent, including the chair, as defined in the Danish
Corporate Governance Recommendations and one member, the employee
representative, who is non-independent. According to the Danish
Corporate Governance Recommendations a majority of the members of a
board committee should qualify as independent. Hence, the composition
of the Research & Development Committee adheres to the Danish
Corporate Governance Recommendations.
The Research & Development Committee conducted six meetings in
2019. All Research & Development Committee members attended all
committee meetings within the member’s term in 2019. Please refer to
the Annual Report 2019 on p. 39 for a detailed attendance
Research & Development
Committee Report for 2019
The R&D Committee works according to an Annual Work Plan with
fixed agenda items. In addition, the R&D Committee meets when
developments require additional meetings. The R&D Committee has in
2019 met six times and dealt with the following matters:
R&D pipeline update
- Regularly reviewed progress of the development project
pipeline, including initiation and results of clinical trials,
submission of application for marketing authorisations, and receipt
of marketing authorisations for key development projects
- Reviewed progress of the research project pipeline, including
key challenges and initiatives within early innovation and new
Progress within external innovation sourcing
- Discussed the increased need for external innovation
- Regularly reviewed potential as well as completed
external innovation sourcing opportunities, including potential
acquisitions and licensing opportunities.
Implementation of the R&D Strategy
- Reviewed the overall investment strategy.
the research strategy within NASH.
- Reviewed the long-term
R&D Committee matters and governance
- Reviewed and endorsed the Annual Work Plan for 2020.
- Reviewed and suggested changes to the R&D Committee
- Conducted private meetings without the assigned
executive being present.
- Reviewed and endorsed a report on
the R&D Committee’s activities.
Special focus areas
- GLP-1 (subcutaneous and oral): Reviewed results of clinical
trials conducted and discussed potential additional research and
development activities to further explore opportunities within
subcutaneous and oral GLP-1 as well as competitor initiatives.
- NASH: Discussed the potential opportunities to address unmet
- External innovation sourcing: Reviewed potential
external research collaborations as well as acquisitions.